Using a 3-<i>O</i>-Sulfated Heparin Octasaccharide To Inhibit the Entry of Herpes Simplex Virus Type 1

Ronald J. Copeland(University of North Carolina at Chapel Hill), Arun Balasubramaniam(University of North Carolina at Chapel Hill), Vaibhav Tiwari(University of North Carolina at Chapel Hill), Fuming Zhang(University of North Carolina at Chapel Hill), Arlene S. Bridges(University of North Carolina at Chapel Hill), Robert J. Linhardt(University of North Carolina at Chapel Hill), Deepak Shukla(University of North Carolina at Chapel Hill), Jian Liu(University of North Carolina at Chapel Hill)
Biochemistry
May 1, 2008
Cited by 126Open Access
Full Text

Abstract

Heparan sulfate (HS) is a highly sulfated polysaccharide and is present in large quantities on the cell surface and in the extracellular matrix. Herpes simplex virus type 1 (HSV-1) utilizes a specialized cell surface HS, known as 3-O-sulfated HS, as an entry receptor to establish infection. Here, we exploit an approach to inhibiting HSV-1 infection by using a 3-O-sulfated octasaccharide, mimicking the active domain of the entry receptor. The 3-O-sulfated octasaccharide was synthesized by incubating a heparin octasaccharide (3-OH octasaccharide) with HS 3-O-sulfotransferase isoform 3. The resultant 3-O-sulfated octasaccharide has a structure of Delta UA2S-GlcNS6S-IdoUA2S-GlcNS6S-IdoUA2S-GlcNS3S6S-IdoUA2S-GlcNS6S (where Delta UA is 4-deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid, GlcN is D-glucosamine, and IdoUA is L-iduronic acid). Results from cell-based assays revealed that the 3-O-sulfated octasaccharide has stronger activity in blocking HSV-1 infection than that of the 3-OH octasaccharide, suggesting that the inhibition of HSV-1 infection requires a unique sulfation moiety. Our results suggest the feasibility of inhibiting HSV-1 infection by blocking viral entry with a specific oligosaccharide.


Related Papers

No related papers found

Powered by citation graph analysis